Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Sterile Saline Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

NCT04475081
View directory record Official record
Conditions
Sepsis Syndrome
Interventions
MMR vaccine
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

Candin for the Treatment of Common Warts

NCT05889845
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Candin, Intradermal Solution, Placebo
Drug
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 24, 2026, 2:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

NCT06282965
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Angiotensin (1-7), Sterile saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 24, 2026, 2:48 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

NCT04347239
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 24, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Not applicable Interventional Results available

Needle-Free Jet Injection of Lidocaine During Lumbar Puncture

NCT01224431
View directory record Official record
Conditions
Pain
Interventions
Buffered Lidocaine J-tip
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 90 Days
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 24, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

NCT03763929
View directory record Official record
Conditions
Stroke, Acute
Interventions
Trans-Sodium Crocetinate, Placebo
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 2:48 AM EDT
Withdrawn Phase 4 Interventional

Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion

NCT02378740
View directory record Official record
Conditions
Anesthesia, Pain, Surgery
Interventions
Saline, Ketamine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

NCT04497389
View directory record Official record
Conditions
SARS CoV-2
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 24, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

NCT05058287
View directory record Official record
Conditions
Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions
Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

NCT04928287
View directory record Official record
Conditions
Parkinson Disease
Interventions
HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Not applicable Interventional Results available

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

NCT02291016
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Formoterol, Placebo
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 2:48 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
Dietary Supplement · Other · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

NCT01409915
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Sagramostim, Saline -- placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 4 Interventional Results available

Septorhinoplasty Post-operative Pain Control With SPG Nerve Block

NCT05667324
View directory record Official record
Conditions
Deviated Nasal Septum
Interventions
Ropivacaine, Dexamethasone, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Preoperative Skin Preparation Evaluation

NCT00636480
View directory record Official record
Conditions
Topical Antisepsis
Interventions
Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 24, 2026, 2:48 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 24, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Safety and PK of AZD0543 in Healthy Adults

NCT07824622
View directory record Official record
Conditions
Human Metapneumovirus Infection
Interventions
AZD0543, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Alamitos, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005
View directory record Official record
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 24, 2026, 2:48 AM EDT